DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Parmax Pharma Ltd (PARMAX) share price today?

Parmax Pharma Ltd (PARMAX) is trading at ₹104.97 on the BSE, up 1.99% on the day. Source: DocStoX.

What is the market capitalisation of Parmax Pharma Ltd?

Parmax Pharma Ltd has a market capitalisation of approximately ₹39 crore.

Parmax Pharma Ltd

PARMAX·BSE·Healthcare

₹104.97▲ +2.05 (+1.99%)

Healthcare · Pharmaceuticals & Biotechnology

Debt-free and consistently profitable

52W₹23

₹103103%

Open

₹104.97

High

₹104.97

Low

₹104.97

Prev Close

₹102.92

Volume

2.0K

VWAP

₹104.97

Snapshot

Key fundamentals

Market Cap

₹39 Cr

P/E Ratio

N/A

P/B Ratio

-5.61

EPS

₹-5.59

Book Value

N/A

ROE

105.30%Strong

ROCE

-12.45%Weak

Dividend Yield

0.00%

Debt / Equity

0.00Low

Face Value

₹10.00

52W High

₹102.92

52W Low

₹22.60

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Fairly Valued

None moatHigh uncertainty

Fair value unavailable

/100

Business quality — Watch the fundamentals

Growth 50Profitability 50Efficiency 0Valuation 100

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet

Strengths

Virtually debt-free balance sheet
Strong returns on equity (105%)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

—

ROE

105.3%Strong

Above 15% is considered healthy for Indian equities

ROCE

-12.4%Weak

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹39 Cr

P/B

-5.61

EPS

₹-5.59

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

N/A

No P/E

Growth

Shrinking

-8% rev CAGR

Profitability

Excellent

105.3% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹2.06L Cr

Trades9

VWAP₹104.97

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

-7.7%

-14.3%

10Y

—

Profit

—

10Y

—

EPS

—

10Y

—

Profile

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of -14.3% over past five years.
Promoter holding is low: 30.8%
Debtor days have increased from 57.4 to 95.2 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

31%

Promoter

Promoters

30.8%0.00

Public

63.1%+0.02

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

6.1%

Total shareholders

2,388-5 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter30.80%

Public63.10%

Others6.10%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1994, Parmax Pharma Ltd manufactures Bulk Drugs, Drug Intermediates & Speciality Chemicals.[1]